Drugs News and Research

RSS

Generative AI-driven drug Rentosertib enters Phase III trial for idiopathic pulmonary fibrosis

Insilico Medicine, a clinical-stage biotechnology company powered by generative AI, today announced that it has dosed the first patient with Rentosertib (known as ISM001-055 / INS018_055) in GENESIS-IPF-3, a Phase III clinical trial (NCT07687459, CTR20262475) at Peking Union Medical College Hospital, while Shanghai Pulmonary Hospital has also enrolled its first patient on the same day.

10 Sep 2026

C. diff uses dual-threat sensing system to survive gut stress

The pathogen Clostridioides difficile (C. diff) - a leading cause of hospital-acquired infections - must contend with a variety of threats inside the harsh environment of the gut to survive and grow.

9 Sep 2026

Digital companion apps help secure long-term habits during GLP-1 therapy

Glucagon-like peptide-1 (GLP-1) medications have revolutionized weight management, yet high dropout rates and rapid weight regain remain significant hurdles for many patients.

9 Sep 2026

New laser-fabricated plasmonic chip accurately identifies and sorts cancer cells

Novel laser-fabricated plasmonic chip combines 185 nm Raman resolution and deep learning to identify and sort cancer cells with 96.2% accuracy.

9 Sep 2026

Researchers develop biodegradable microneedle particles to enhance drug delivery

Researchers have developed biodegradable particles with microscopic needles that painlessly puncture the skin to help it absorb drugs delivered through patches or creams.

9 Sep 2026

Johns Hopkins researchers identify human resistin as a key driver of inflammation

Researchers at Johns Hopkins Medicine have uncovered a critical biological mechanism that helps explain how inflammation is triggered and sustained in a wide range of diseases-highlighting a promising avenue for future therapeutic development.

9 Sep 2026

Study uncovers bacterial weakness during flagellum construction

New research from Indiana University has uncovered a previously unknown vulnerability in how bacteria build the whip-like tails they use to move.

8 Sep 2026

Retinal immune cell gateway may unlock targeted uveitis treatments

As part of an effort to understand the molecules and mechanisms that regulate transendothelial migration in different vascular beds of the body, researchers focused on the blood vessels of the retina, part of the blood-brain barrier.

8 Sep 2026

Vitamin A derivative prevents immune cell exhaustion in brain tumors

Immune cells can become exhausted after prolonged exposure to cancer, gradually losing their ability to attack tumor cells.

8 Sep 2026

Healthy midlife choices add both years and quality to life

In a 50-year follow-up study, men with a low cardiovascular risk in their 40s retained their functional capacity, happiness and quality of life better than others as they aged.

8 Sep 2026

New AI model decodes chemical signals guiding embryonic cell development

As an embryo develops from a small cluster of stem cells, those once "blank slate" cells begin to take on more specialized roles like brain, liver, or muscle cells, and organize themselves into three-dimensional structures such as tissues and organs.

8 Sep 2026

LSD deconstruction reveals promising new drug candidates

University of California, Davis researchers have stripped down LSD to the base features responsible for its hallucinogenic and therapeutic effects.

7 Sep 2026

Scientists discover new mechanism for bacterial fosfomycin resistance

Bacteria can survive antibiotics in several ways, including by pumping the drugs out of their cells before they can take effect.

7 Sep 2026

The vaginal microbiome may be an overlooked reservoir of antibiotic resistance

Researchers analyzed 1,957 vaginal metagenomic samples from 1,547 pregnant women and found that bacterial community structure was strongly associated with the diversity and distribution of clinically relevant antibiotic resistance genes. Lactobacillus crispatus-dominated communities carried comparatively few acquired resistance genes, while L. iners-dominated and anaerobe-rich communities showed greater resistance diversity, with PPROM associated with broader predicted resistance profiles among ARG-positive samples.

7 Sep 2026

GLP-1 drugs looked promising for depression. The evidence tells a more complicated story

A systematic review of 43 studies found highly heterogeneous results for GLP-1 receptor agonists across animal models and human research assessing depression-, anxiety-, and stress-related outcomes. No study directly tested these drugs as a treatment for PTSD, and the available evidence does not currently support their use for depression or PTSD, although people with metabolic dysfunction may warrant further investigation.

7 Sep 2026

Psilocybin microdosing sounds promising, but the strongest studies tell a different story

A systematic review of 11 studies involving 3,262 adults found that psilocybin mushroom and truffle microdosing was associated with reported improvements across areas including mental health, well-being, cognition, creativity, and social functioning. However, the evidence was methodologically weak and highly heterogeneous, the two placebo-controlled trials found no significant improvements, and inadequate adverse-event reporting means efficacy and safety remain uncertain.

7 Sep 2026

Elusive stem cells offer clues to treat lumbar spinal stenosis

Researchers at Weill Cornell Medicine and Hospital for Special Surgery have discovered the stem cells—unspecialized cells that can develop into specific cell types—that give rise to the body's tendons and ligaments, the tissues connecting muscles and bones.

7 Sep 2026

Experimental cancer drug could protect against osteoporosis and weight gain

An experimental cancer drug could stop osteoporosis and help women stay slim after the menopause – according to new research from the University of East Anglia.

7 Sep 2026

AI-designed drug candidate reverses biological age in clinical study

Insilico Medicine ("Insilico"), a clinical-stage company focused on generative AI-driven drug discovery and development, today announced the publication of a new study conducted in collaboration with an international team of scientists from Harvard Medical School, Stanford University, The Broad Institute, RWTH Aachen University, Peking University and Westlake University.

7 Sep 2026

GLP-1 drugs appear psychiatrically safe, but one finding still raises questions

A systematic review of 11 observational studies representing more than 4.9 million patients found that GLP-1 receptor agonists were generally associated with neutral or potentially protective psychiatric outcomes, although one obesity-focused cohort reported increased risks of depression, anxiety, and suicidal behavior. Direct evidence for antidepressant effects remains limited, with only one cross-sectional study using validated mood scales and no randomized trials in the final synthesis, meaning causality cannot be established

6 Sep 2026